M&A / Deals Novartis and Chai Discovery collaborate on antibody identification Pharmaceutical TechnologyNovartis has entered a collaboration with Chai Discovery to advance the use of AI in the identification of therapeutic antibodies.Read full story pharminent July 14, 2026 (Last updated: July 14, 2026) Pharmaceutical Technology Novartis has entered a collaboration with Chai Discovery to advance the use of AI in the identification of therapeutic antibodies. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA clears at-home start dose for Alzheimer’s drug LeqembiNext: AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B Related Stories M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026 M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026
